Weight loss drugs like Wegovy and Zepbound, based on GLP-1, are being researched for a variety of conditions beyond weight loss and diabetes.
These drugs show promise in reducing the risk of heart attack or stroke in overweight individuals with heart problems, with potential benefits beyond just weight loss.
Incretin-based weight-loss drugs like Zepbound may have secondary effects on inflammation from visceral fat, offering exciting new research avenues.
[
Collection
]
[
|
...
]